Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1158118.RAXqCa20ucByoLFDqZaKN7Vz3g46bih3lr531DWETru5A130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1158118.RAXqCa20ucByoLFDqZaKN7Vz3g46bih3lr531DWETru5A130_assertion type Assertion NP1158118.RAXqCa20ucByoLFDqZaKN7Vz3g46bih3lr531DWETru5A130_head.
- NP1158118.RAXqCa20ucByoLFDqZaKN7Vz3g46bih3lr531DWETru5A130_assertion description "[Leptin antagonists have been developed for clinical use and leptin and its associated pathways may also provide much needed novel therapeutic targets for gastro-oesophageal adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1158118.RAXqCa20ucByoLFDqZaKN7Vz3g46bih3lr531DWETru5A130_provenance.
- NP1158118.RAXqCa20ucByoLFDqZaKN7Vz3g46bih3lr531DWETru5A130_assertion evidence source_evidence_literature NP1158118.RAXqCa20ucByoLFDqZaKN7Vz3g46bih3lr531DWETru5A130_provenance.
- NP1158118.RAXqCa20ucByoLFDqZaKN7Vz3g46bih3lr531DWETru5A130_assertion SIO_000772 24569475 NP1158118.RAXqCa20ucByoLFDqZaKN7Vz3g46bih3lr531DWETru5A130_provenance.
- NP1158118.RAXqCa20ucByoLFDqZaKN7Vz3g46bih3lr531DWETru5A130_assertion wasDerivedFrom befree-2016 NP1158118.RAXqCa20ucByoLFDqZaKN7Vz3g46bih3lr531DWETru5A130_provenance.
- NP1158118.RAXqCa20ucByoLFDqZaKN7Vz3g46bih3lr531DWETru5A130_assertion wasGeneratedBy ECO_0000203 NP1158118.RAXqCa20ucByoLFDqZaKN7Vz3g46bih3lr531DWETru5A130_provenance.